Concepedia

Author

Marcus Smith Noel

University of Rochester Medical CenterORCID

Also Known As

Jen-Shi Chen, M S Noel, M. Noel, M.S. Noel, Marcus Noel, Marcus S Noel, Marcus S. Noel, Marcus Smith Noel

162

Publications

1.5K

Citations

17

H-Index

29

Concepts

All Affiliations

University of Rochester Medical CenterGeorgetown University Medical CenterGeorgetown UniversityUniversity of RochesterMassachusetts General Hospital
MS

About

Marcus Smith Noel is an author at University of Rochester Medical Center specializing in medicine, oncology, and radiation oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

7

7

266

2

Health Sciences

2

2

47

3

Nursing

1

1

64

4

Family Medicine

1

1

64

5

Geriatrics

1

1

64

Marcus Smith Noel

×

18

Publications

952

Citations

13

H-Index

YearCitations

Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma

Marcus Smith Noel, Eileen M. O’Reilly, Brian M. Wolpin,

Investigational New Drugs

2019

174

Adjuvant <i>nab</i> -Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial

Margaret A. Tempero, Uwe Pelzer, Eileen M. O’Reilly,

Journal of Clinical Oncology

2022

120

Comparison of outcomes between SBRT, yttrium-90 radioembolization, transarterial chemoembolization, and radiofrequency ablation as bridge to transplant for hepatocellular carcinoma

Mostafa Mohamed, Alan W. Katz, Mohamedtaki Abdulaziz Tejani,

Advances in Radiation Oncology

2015

93

Overall survival in a trial of orally administered CCR2 inhibitor CCX872 in locally advanced/metastatic pancreatic cancer: Correlation with blood monocyte counts.

David C. Linehan, Marcus Smith Noel, Aram F. Hezel,

Journal of Clinical Oncology

2018

90

Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131)

Douglas B. Johnson, Fengmin Zhao, Marcus Smith Noel,

Clinical Cancer Research

2020

88

Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies

Gerald S. Falchook, Seth Rosen, Patricia LoRusso,

Clinical Cancer Research

2019

78

Geriatric assessment with management intervention in older adults with cancer: a randomized pilot study

Allison Magnuson, Tatyana Lemelman, Chintan Pandya,

Supportive Care in Cancer

2017

64

Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer

Aram F. Hezel, Marcus Smith Noel, Jill N. Allen,

British Journal of Cancer

2014

58

Orally administered CCR2 selective inhibitor CCX872-b clinical trial in pancreatic cancer.

Marcus Smith Noel, Aram F. Hezel, David C. Linehan,

Journal of Clinical Oncology

2017

36

Randomized phase II study of second-line modified FOLFIRI with PARP inhibitor ABT-888 (Veliparib) (NSC-737664) versus FOLFIRI in metastatic pancreatic cancer (mPC): SWOG S1513.

E. Gabriela Chiorean, Katherine A. Guthrie, Philip Agop Philip,

Journal of Clinical Oncology

2019

32

Page 1